grant
An engineered prodrug for inhibition of cancer growth and metastasis
Organization UNIVERSITY OF MARYLAND BALTIMORELocation BALTIMORE, UNITED STATESPosted 3 Jan 2025Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2025AddressAntimitotic AgentsAntimitotic DrugsAntimitoticsAnzataxAsotaxB anthracisB. anthracisBacillus anthracisBacteriaBiodistributionBiologicalBiologyBlood PlasmaBristaxolCBDCACancer cell lineCancersCarboplatinCarboplatinoCause of DeathCell BodyCell LineCell SurvivalCell ViabilityCell surfaceCellLineCellsChemoresistanceClassificationClinicClinicalClinical ManagementColon CancerColon CarcinomaCombination Drug TherapyCytotoxic agentCytotoxic drugCytotoxinDataDebulkingDisablingDiseaseDisease remissionDisorderDoseDrug DeliveryDrug Delivery SystemsDrug DesignDrug PrecursorsDrug TherapyDrugsEngineeringEnzyme GeneEnzyme PrecursorsEnzymesEpithelial ovarian cancerEsteroproteasesEvolutionExotoxinsExposure toExtracellular Signal-Regulated Kinase GeneFamilyFemale Reproductive CancerGeneralized GrowthGoalsGrowthGynecologic CancerGynecological CancerHalf-LifeHumanHyperactivityImmunityIn VitroInfectionIntoxicationLeTxLifeLytotoxicityMAP Kinase GeneMAPKMalignantMalignant - descriptorMalignant CellMalignant Female Reproductive System NeoplasmMalignant Gynecologic NeoplasmMalignant Gynecologic TumorMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the Female Reproductive SystemMalignant Tumor of the LungMalignant Tumor of the OvaryMalignant neoplasm of lungMalignant neoplasm of ovaryMedicationMembraneMetabolicMetallopeptidasesMetalloproteasesMetalloproteinasesMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMetastatic/RecurrentMicrotubular Function InhibitorsMitogen-Activated Protein Kinase GeneMitosis Inhibitor AgentsMitosis Inhibitor DrugsMitosis InhibitorsMitotic Inhibitor AgentsMitotic Inhibitor DrugsMitotic InhibitorsModelingModern ManMolecularNeoplasm MetastasisNon-MalignantOncogenicOvarianOvarian TumorOvary CancerOvary NeoplasmsOvary TumorPDX modelPK/PDPaclitaxelPaclitaxel (Taxol)PathologicPathway interactionsPatient derived xenograftPatientsPeptidasesPeptide HydrolasesPharmaceutical PreparationsPharmacodynamicsPharmacological TreatmentPharmacotherapyPlasmaPlasma SerumPlatinumPlatinum BlackPolychemotherapyPraxelPre-Clinical ModelPreclinical ModelsPredispositionPrimary NeoplasmPrimary TumorPro-DrugsProdrugsProenzymesPrognosisPropertyProtease GeneProteasesProtein EngineeringProteinasesProteinsProteolytic EnzymesPt elementPulmonary CancerPulmonary malignant NeoplasmRecurrenceRecurrentRemissionResistanceReticuloendothelial System, Serum, PlasmaSecondary NeoplasmSecondary TumorSerine EndopeptidasesSerine ProteaseSerine Protein HydrolasesSerine ProteinasesSerousSignal PathwaySolid NeoplasmSolid TumorStrains Cell LinesSurfaceSurvival RateSusceptibilitySystemSystematicsTaxolTaxol ATaxol KonzentratTestingTherapeuticTissue GrowthTumor CellTumor DebulkingTumor PromotionUnited StatesVirulentWomanZymogensadvanced diseaseadvanced illnessanthracisanthrax toxinanti-cancerbiologiccancer cellcancer in the coloncancer metastasischemoresistantchemotherapeutic agentchemotherapeutic compoundschemotherapeutic drugschemotherapeutic medicationschemotherapychemotherapy resistancechemotherapy resistantclinical applicabilityclinical applicationcombination chemotherapycombination pharmacotherapycultured cell linecytoreductive surgerycytotoxiccytotoxicitydetermine efficacydrug actiondrug interventiondrug treatmentdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsgenetic protein engineeringgynecologic malignancygynecological malignancyimprovedimproved outcomein vivoin vivo Modelinsightintervention designlethal factorlethal toxinlung cancermalignancymembrane structuremouse modelmurine modelmutational statusneoplasm/cancerneoplastic cellnew drug classnonmalignantnovelnovel drug classontogenyovarian cancerovarian neoplasmpathwaypatient derived xenograft modelpatient stratificationpharmaceutical interventionpharmacokinetics and pharmacodynamicspharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspre-clinicalpreclinicalprotein designprototyperesistantside effectstandard of carestratified patientsurgical cytoreductiontargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttaxanetherapeutic agent developmenttherapeutic candidatetherapeutic developmenttherapeutically effectivetherapy designtreatment designtumortumor cell metastasistumor cytoreductiontumor growthtumor specificitytumor xenograftweapons
Description preview
Treatments for metastatic and recurrent solid tumors, including ovarian, lung and colon cancers, remain a
challenge due to lack of potent, selective and effective therapeutics. Clinically approved chemotherapies aim to
slow or stop tumor growth; however, cancer cells continue to evolve between chemotherapy cycles, acquiring
properties that allow…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click